NovaBay Pharmaceuticals Reports 2017 Fourth Quarter and Full Year Financial Results
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing prescription Avenova® for the domestic eye care market, reports financial results for the three and 12 months ended December 31, 2017 and provides a business update. “I’m pleased to announce strong fourth quarter financial performance and full year sales of $18.2 million, which is at the high end of our guidance range,” said Mark M. Sieczkarek, NovaBa